AOD-9604 vs MOTS-c
Both compounds have been investigated for metabolic endpoints, but through different mechanisms and at different stages of preclinical and clinical characterisation. AOD-9604 is a modified growth-hormone C-terminal fragment studied for lipolytic activity. MOTS-c is an endogenous mitochondrial-derived peptide studied for AMPK-pathway activation. This page summarises the published research distinctions.
Side-by-side comparison
| Property | Compound A | Compound B |
|---|---|---|
| Structural class | Modified C-terminal fragment (AA 177-191) of human growth hormone | 16-residue peptide encoded within the mitochondrial 12S rRNA gene |
| Mechanism | Proposed lipolytic activity via incompletely characterised pathway; no GH receptor binding | AMPK pathway activation; nuclear translocation under metabolic stress |
| Primary research domain | Adipose-tissue pharmacology; more recently intra-articular cartilage | Metabolic homeostasis, insulin resistance, exercise physiology |
| Evidence maturity | Phase 2b clinical trial for obesity (did not advance); more recent preclinical osteoarthritis work | Preclinical only; rodent and cell-culture models |
| Common research routes | Subcutaneous, oral, intra-articular | Subcutaneous, intraperitoneal |
| Ronin catalog vial size | 5 mg lyophilised | 10 mg lyophilised |
How they differ in mechanism
AOD-9604 is a modified C-terminal fragment of human growth hormone (amino acids 177-191). The compound does not bind the GH receptor, and the signalling pathway mediating its lipolytic effects is incompletely characterised. The Heffernan et al. studies demonstrated fat oxidation and weight loss in obese rodent models without growth-promoting effects. The compound did not advance through Phase 2b clinical development for metabolic indications. More recent work has investigated intra-articular injection for osteoarthritis endpoints.
MOTS-c has a 16-residue sequence encoded by the mitochondrial 12S rRNA gene and activates the AMPK pathway. The peptide translocates to the nucleus under metabolic stress to regulate the nuclear transcriptome. Functional endpoints span metabolic homeostasis, insulin sensitivity, exercise capacity, and neuropathic-pain modulation in rodent models. The mitochondrial origin provides a distinct biological context from synthetic receptor agonists or receptor fragments.
Both compounds have been studied for metabolic effects in rodent models, but the molecular pathways are unrelated. AOD-9604 acts through an undefined lipolytic mechanism related to GH-fragment pharmacology. MOTS-c acts through AMPK-mediated metabolic-stress signalling. Neither has advanced to late-stage clinical development for metabolic indications.
How research has examined each
The AOD-9604 literature centres on rodent adipose-tissue pharmacology from the Heffernan studies (2000, 2001), detection and metabolism work (Cox et al., 2015), WADA-related analytical work (Orlovius et al., 2013), and more recent osteoarthritis investigation (Kwon et al., 2015). The clinical development history for obesity ended before Phase 3.
The MOTS-c literature has expanded across metabolic homeostasis, exercise physiology, neuropathic pain, cardiovascular endpoints, and radiation protection since the 2015 characterisation. The peptide’s endogenous mitochondrial origin and AMPK-activation mechanism distinguish it from synthetic peptide fragments.
Both compounds are in early-to-mid preclinical positioning for metabolic research. Neither has a robust late-stage clinical dataset. A researcher reading both is reading two different preclinical metabolic-peptide stories with different mechanistic foundations.
Stacking considerations in research contexts
Combined administration of AOD-9604 and MOTS-c is not described in published research. The mechanisms are unrelated. AOD-9604 ships at 5 mg and MOTS-c at 10 mg in the Ronin catalog, both as lyophilised vials.
Sourcing both at Ronin
Both compounds ship as lyophilised peptide in glass vials with certificate-of-analysis documentation. The AOD-9604 vial page provides 5 mg per vial. The MOTS-c vial page provides 10 mg per vial. Both are research-grade reagents.
Frequently asked research questions
Are AOD-9604 and MOTS-c related?
No. AOD-9604 is a modified GH C-terminal fragment. MOTS-c is a mitochondrial-derived peptide. Different origins and mechanisms.
Do they target the same pathway?
No. AOD-9604 acts through an incompletely characterised lipolytic pathway. MOTS-c activates the AMPK pathway.
Are either clinically approved?
Neither is FDA or Health Canada approved. Both are research-grade reagents.
Why is the AOD-9604 vial smaller?
AOD-9604 is supplied at 5 mg per vial, reflecting standard research-supply conventions for this compound.
Are they co-administered?
Not in published research.
References
- Heffernan MA et al. Increase of fat oxidation and weight loss in obese mice caused by human growth hormone or a modified C-terminal fragment. International Journal of Obesity, 2001. [PMID 11673763]
- Wilding J. AOD-9604 Metabolic. Current Opinion in Investigational Drugs, 2004. [PMID 15134286]
- Lee C et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis. Cell Metabolism, 2015. [PMID 25738459]
- Kim KH et al. MOTS-c translocates to the nucleus to regulate nuclear gene expression. Cell Metabolism, 2018. [PMID 29983246]
- Wan W et al. MOTS-c: effects and mechanisms related to stress, metabolism and aging. Journal of Translational Medicine, 2023. [PMID 36670507]
Comparison pages describe research-context use of the compared compounds. They do not constitute medical, veterinary, or clinical advice. Every compound in the Ronin catalog is sold strictly for laboratory and research use only.